Skip to main content
Top
Published in: Endocrine 1/2019

Open Access 01-04-2019 | Original Article

Factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission

Authors: Marie Helene Schernthaner-Reiter, Christina Siess, Alois Gessl, Christian Scheuba, Stefan Wolfsberger, Philipp Riss, Engelbert Knosp, Anton Luger, Greisa Vila

Published in: Endocrine | Issue 1/2019

Login to get access

Abstract

Purpose

In Cushing’s syndrome, comorbidities often persist after remission of glucocorticoid excess. Here, we aim to identify factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission.

Methods

In a retrospective cross-sectional study, 118 patients with Cushing’s syndrome in remission (52 pituitary, 58 adrenal, 8 ectopic) were followed for a median of 7.9 years (range 2–38) after the last surgery. Associations between baseline anthropometric, metabolic, hormonal parameters at diagnosis, and comorbidities (obesity, diabetes, hyperlipidemia, hypertension, osteoporosis, depression) at last follow-up, were tested by uni- and multivariate regression analysis.

Results

In patients with manifest comorbidities at diagnosis, remission of Cushing’s syndrome resolved diabetes in 56% of cases, hypertension in 36% of cases, hyperlipidaemia in 23%, and depression in 52% of cases. In a multivariate regression analysis, age, fasting glucose, BMI, and the number of comorbidities at diagnosis were positive predictors of the number of long-term comorbidities, while baseline 24-h urinary free cortisol (UFC) negatively correlated with the persistence of long-term comorbidities. The negative relationship between baseline UFC and long-term comorbidities was also found when pituitary and adrenal Cushing’s cases were analyzed separately. Baseline UFC was negatively related to the time of exposure to excess glucocorticoids.

Conclusions

Long-term comorbidities after remission of Cushing’s syndrome depend not only on the presence of classic cardiovascular risk factors (age, hyperglycemia, BMI), but also on the extent of glucocorticoid excess. Lower baseline UFC is associated with a higher number of long-term comorbidities, possibly due to the longer exposure to excess glucocorticoids in milder Cushing’s syndrome.
Appendix
Available only for authorised users
Literature
1.
go back to reference R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M. Biller, A. Colao, Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 4, 611–629 (2016)CrossRefPubMed R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M. Biller, A. Colao, Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 4, 611–629 (2016)CrossRefPubMed
2.
go back to reference A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing’s syndrome. Lancet 386, 913–927 (2015)CrossRefPubMed A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing’s syndrome. Lancet 386, 913–927 (2015)CrossRefPubMed
3.
go back to reference J.K. Lambert, L. Goldberg, S. Fayngold, J. Kostadinov, K.D. Post, E.B. Geer, Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J. Clin. Endocrinol. Metab. 98, 1022–1030 (2013)CrossRefPubMedPubMedCentral J.K. Lambert, L. Goldberg, S. Fayngold, J. Kostadinov, K.D. Post, E.B. Geer, Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J. Clin. Endocrinol. Metab. 98, 1022–1030 (2013)CrossRefPubMedPubMedCentral
4.
go back to reference R.N. Clayton, P.W. Jones, R.C. Reulen, P.M. Stewart, Z.K. Hassan-Smith, G. Ntali, N. Karavitaki, O.M. Dekkers, A.M. Pereira, M. Bolland, I. Holdaway, J. Lindholm, Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 4, 569–576 (2016)CrossRefPubMed R.N. Clayton, P.W. Jones, R.C. Reulen, P.M. Stewart, Z.K. Hassan-Smith, G. Ntali, N. Karavitaki, O.M. Dekkers, A.M. Pereira, M. Bolland, I. Holdaway, J. Lindholm, Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 4, 569–576 (2016)CrossRefPubMed
5.
go back to reference E. Valassi, A. Santos, M. Yaneva, M. Toth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, ERCUSYN Study Group, The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol 165, 383–392 (2011) E. Valassi, A. Santos, M. Yaneva, M. Toth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, ERCUSYN Study Group, The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol 165, 383–392 (2011)
6.
go back to reference R.A. Feelders, S.J. Pulgar, A. Kempel, A.M. Pereira, The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur. J. Endocrinol. 167, 311–326 (2012)CrossRefPubMed R.A. Feelders, S.J. Pulgar, A. Kempel, A.M. Pereira, The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur. J. Endocrinol. 167, 311–326 (2012)CrossRefPubMed
7.
go back to reference R. Giordano, A. Picu, E. Marinazzo, V. D’Angelo, R. Berardelli, I. Karamouzis, D. Forno, D. Zinna, M. Maccario, E. Ghigo, E. Arvat, Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin. Endocrinol. (Oxf.). 75, 354–360 (2011)CrossRefPubMed R. Giordano, A. Picu, E. Marinazzo, V. D’Angelo, R. Berardelli, I. Karamouzis, D. Forno, D. Zinna, M. Maccario, E. Ghigo, E. Arvat, Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin. Endocrinol. (Oxf.). 75, 354–360 (2011)CrossRefPubMed
8.
go back to reference T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. (Oxf.) 61, 768–777 (2004)CrossRef T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. (Oxf.) 61, 768–777 (2004)CrossRef
9.
go back to reference O.M. Dekkers, E. Horvath-Puho, J.O. Jorgensen, S.C. Cannegieter, V. Ehrenstein, J.P. Vandenbroucke, A.M. Pereira, H.T. Sorensen, Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013)CrossRefPubMed O.M. Dekkers, E. Horvath-Puho, J.O. Jorgensen, S.C. Cannegieter, V. Ehrenstein, J.P. Vandenbroucke, A.M. Pereira, H.T. Sorensen, Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013)CrossRefPubMed
10.
go back to reference D. Hirsch, I. Shimon, Y. Manisterski, N. Aviran-Barak, O. Amitai, V. Nadler, S. Alboim, V. Kopel, G. Tsvetov, Cushing’s syndrome: Comparison between Cushing’s disease and adrenal Cushing’s. Endocrine 62, 512–520 (2018)CrossRef D. Hirsch, I. Shimon, Y. Manisterski, N. Aviran-Barak, O. Amitai, V. Nadler, S. Alboim, V. Kopel, G. Tsvetov, Cushing’s syndrome: Comparison between Cushing’s disease and adrenal Cushing’s. Endocrine 62, 512–520 (2018)CrossRef
11.
go back to reference M.V. Cicala, F. Mantero, Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology 92(Suppl 1), 44–49 (2010)CrossRefPubMed M.V. Cicala, F. Mantero, Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology 92(Suppl 1), 44–49 (2010)CrossRefPubMed
12.
go back to reference C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170, 311–319 (2014)CrossRefPubMed C. Giordano, V. Guarnotta, R. Pivonello, M.C. Amato, C. Simeoli, A. Ciresi, A. Cozzolino, A. Colao, Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 170, 311–319 (2014)CrossRefPubMed
13.
go back to reference V. Guarnotta, M.C. Amato, R. Pivonello, G. Arnaldi, A. Ciresi, L. Trementino, R. Citarrella, D. Iacuaniello, G. Michetti, C. Simeoli, A. Colao, C. Giordano, The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome. Endocrine 55, 564–572 (2017)CrossRefPubMed V. Guarnotta, M.C. Amato, R. Pivonello, G. Arnaldi, A. Ciresi, L. Trementino, R. Citarrella, D. Iacuaniello, G. Michetti, C. Simeoli, A. Colao, C. Giordano, The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome. Endocrine 55, 564–572 (2017)CrossRefPubMed
14.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Endocrine Society, Treatment of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 100, 2807–2831 (2015) L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Endocrine Society, Treatment of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 100, 2807–2831 (2015)
15.
go back to reference A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella, P. Marzullo, G. Cerbone, M. Siciliani, G. Lombardi, Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84, 2664–2672 (1999)PubMed A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella, P. Marzullo, G. Cerbone, M. Siciliani, G. Lombardi, Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84, 2664–2672 (1999)PubMed
16.
go back to reference G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Bohm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, J. Redon, A. Dominiczak, K. Narkiewicz, P.M. Nilsson, M. Burnier, M. Viigimaa, E. Ambrosioni, M. Caufield, A. Coca, M.H. Olsen, R.E. Schmieder, C. Tsioufis, P. van de Borne, J.L. Zamorano, S. Achenbach, H. Baumgartner, J.J. Bax, H. Bueno, V. Dean, C. Deaton, C. Erol, R. Fagard, R. Ferrari, D. Hasdai, A.W. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M.F. Piepoli, P. Ponikowski, P.A. Sirnes, J.L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, D.L. Clement, A. Coca, T.C. Gillebert, M. Tendera, E.A. Rosei, E. Ambrosioni, S.D. Anker, J. Bauersachs, J.B. Hitij, M. Caulfield, M. De Buyzere, S. De Geest, G.A. Derumeaux, S. Erdine, C. Farsang, C. Funck-Brentano, V. Gerc, G. Germano, S. Gielen, H. Haller, A.W. Hoes, J. Jordan, T. Kahan, M. Komajda, D. Lovic, H. Mahrholdt, M.H. Olsen, J. Ostergren, G. Parati, J. Perk, J. Polonia, B.A. Popescu, Z. Reiner, L. Ryden, Y. Sirenko, A. Stanton, H. Struijker-Boudier, C. Tsioufis, P. van de Borne, C. Vlachopoulos, M. Volpe, D.A. Wood, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34, 2159–2219 (2013)CrossRefPubMed G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Bohm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, J. Redon, A. Dominiczak, K. Narkiewicz, P.M. Nilsson, M. Burnier, M. Viigimaa, E. Ambrosioni, M. Caufield, A. Coca, M.H. Olsen, R.E. Schmieder, C. Tsioufis, P. van de Borne, J.L. Zamorano, S. Achenbach, H. Baumgartner, J.J. Bax, H. Bueno, V. Dean, C. Deaton, C. Erol, R. Fagard, R. Ferrari, D. Hasdai, A.W. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M.F. Piepoli, P. Ponikowski, P.A. Sirnes, J.L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, D.L. Clement, A. Coca, T.C. Gillebert, M. Tendera, E.A. Rosei, E. Ambrosioni, S.D. Anker, J. Bauersachs, J.B. Hitij, M. Caulfield, M. De Buyzere, S. De Geest, G.A. Derumeaux, S. Erdine, C. Farsang, C. Funck-Brentano, V. Gerc, G. Germano, S. Gielen, H. Haller, A.W. Hoes, J. Jordan, T. Kahan, M. Komajda, D. Lovic, H. Mahrholdt, M.H. Olsen, J. Ostergren, G. Parati, J. Perk, J. Polonia, B.A. Popescu, Z. Reiner, L. Ryden, Y. Sirenko, A. Stanton, H. Struijker-Boudier, C. Tsioufis, P. van de Borne, C. Vlachopoulos, M. Volpe, D.A. Wood, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34, 2159–2219 (2013)CrossRefPubMed
17.
go back to reference American Diabetes Association. (2) Classification and diagnosis of diabetes, Diabetes Care 38, Suppl:S8–Suppl:S16 (2015) American Diabetes Association. (2) Classification and diagnosis of diabetes, Diabetes Care 38, Suppl:S8–Suppl:S16 (2015)
18.
go back to reference National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002) National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002)
19.
go back to reference K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998)CrossRefPubMed K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998)CrossRefPubMed
20.
go back to reference J. Klimont, E. Baldaszti. Austrian Health Interview Survey 2014 (ATHIS) (Österreichische Gesundheitsbefragung 2014, Hauptergebnisse und methodische Dokumentation). (Statistik Austria, Vienna, 2015) J. Klimont, E. Baldaszti. Austrian Health Interview Survey 2014 (ATHIS) (Österreichische Gesundheitsbefragung 2014, Hauptergebnisse und methodische Dokumentation). (Statistik Austria, Vienna, 2015)
21.
go back to reference R. Griebler, P. Winkler, S. Gaiswinkler, J. Delcour, B. Juraszovich, M. Nowotny, E. Pochobradsky, B. Schleicher, I. Schmutterer. Austrian Health Report 2016 (Österreichischer Gesundheitsbericht 2016.). (Federal Ministry of Health and Women, Vienna, 2017) R. Griebler, P. Winkler, S. Gaiswinkler, J. Delcour, B. Juraszovich, M. Nowotny, E. Pochobradsky, B. Schleicher, I. Schmutterer. Austrian Health Report 2016 (Österreichischer Gesundheitsbericht 2016.). (Federal Ministry of Health and Women, Vienna, 2017)
22.
go back to reference G. Mazziotti, A.M. Formenti, S. Frara, F. Maffezzoni, M. Doga, A. Giustina, Diabetes in Cushing disease. Curr. Diab. Rep. 17, 32 (2017)CrossRefPubMed G. Mazziotti, A.M. Formenti, S. Frara, F. Maffezzoni, M. Doga, A. Giustina, Diabetes in Cushing disease. Curr. Diab. Rep. 17, 32 (2017)CrossRefPubMed
23.
go back to reference A.M. Isidori, C. Graziadio, R.M. Paragliola, A. Cozzolino, A.G. Ambrogio, A. Colao, S.M. Corsello, R. Pivonello; Group ABCS, The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J. Hypertens. 33, 44–60 (2015)CrossRefPubMedPubMedCentral A.M. Isidori, C. Graziadio, R.M. Paragliola, A. Cozzolino, A.G. Ambrogio, A. Colao, S.M. Corsello, R. Pivonello; Group ABCS, The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J. Hypertens. 33, 44–60 (2015)CrossRefPubMedPubMedCentral
24.
go back to reference A. Faggiano, R. Pivonello, S. Spiezia, M.C. De Martino, M. Filippella, C. Di Somma, G. Lombardi, A. Colao, Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88, 2527–2533 (2003)CrossRefPubMed A. Faggiano, R. Pivonello, S. Spiezia, M.C. De Martino, M. Filippella, C. Di Somma, G. Lombardi, A. Colao, Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88, 2527–2533 (2003)CrossRefPubMed
25.
go back to reference E.B. Geer, W. Shen, E. Strohmayer, K.D. Post, P.U. Freda, Body composition and cardiovascular risk markers after remission of Cushing’s disease: a prospective study using whole-body MRI. J. Clin. Endocrinol. Metab. 97, 1702–1711 (2012)CrossRefPubMedPubMedCentral E.B. Geer, W. Shen, E. Strohmayer, K.D. Post, P.U. Freda, Body composition and cardiovascular risk markers after remission of Cushing’s disease: a prospective study using whole-body MRI. J. Clin. Endocrinol. Metab. 97, 1702–1711 (2012)CrossRefPubMedPubMedCentral
26.
go back to reference M.J. Barahona, N. Sucunza, E. Resmini, J.M. Fernandez-Real, W. Ricart, J.M. Moreno-Navarrete, T. Puig, J. Farrerons, S.M. Webb, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 94, 3365–3371 (2009)CrossRefPubMed M.J. Barahona, N. Sucunza, E. Resmini, J.M. Fernandez-Real, W. Ricart, J.M. Moreno-Navarrete, T. Puig, J. Farrerons, S.M. Webb, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 94, 3365–3371 (2009)CrossRefPubMed
27.
go back to reference J. Tiemensma, N.R. Biermasz, H.A. Middelkoop, R.C. van der Mast, J.A. Romijn, A.M. Pereira, Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s disease. J. Clin. Endocrinol. Metab. 95, E129–E141 (2010)CrossRefPubMed J. Tiemensma, N.R. Biermasz, H.A. Middelkoop, R.C. van der Mast, J.A. Romijn, A.M. Pereira, Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s disease. J. Clin. Endocrinol. Metab. 95, E129–E141 (2010)CrossRefPubMed
28.
go back to reference C.D. Andela, F.M. van Haalen, O. Ragnarsson, E. Papakokkinou, G. Johannsson, A. Santos, S.M. Webb, N.R. Biermasz, N.J. van der Wee, A.M. Pereira, Mechanisms in endocrinology: Cushing’s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur. J. Endocrinol. 173, R1–R14 (2015)CrossRefPubMed C.D. Andela, F.M. van Haalen, O. Ragnarsson, E. Papakokkinou, G. Johannsson, A. Santos, S.M. Webb, N.R. Biermasz, N.J. van der Wee, A.M. Pereira, Mechanisms in endocrinology: Cushing’s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur. J. Endocrinol. 173, R1–R14 (2015)CrossRefPubMed
29.
go back to reference J.R. Lindsay, T. Nansel, S. Baid, J. Gumowski, L.K. Nieman, Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab. 91, 447–453 (2006)CrossRefPubMed J.R. Lindsay, T. Nansel, S. Baid, J. Gumowski, L.K. Nieman, Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab. 91, 447–453 (2006)CrossRefPubMed
30.
go back to reference E. Valassi, R. Feelders, D. Maiter, P. Chanson, M. Yaneva, M. Reincke, M. Krsek, M.Toth, S.M. Webb, A. Santos, I. Paiva, I. Komerdus, M. Droste, A. Tabarin, C.J. Strasburger, H. Franz, P.J. Trainer, J. Newell-Price, J.A. Wass, E. Papakokkinou, O. Ragnarsson, ERCUSYN Study Group, Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN. Clin. Endocrinol. (Oxf.). 88, 787–798 (2018) E. Valassi, R. Feelders, D. Maiter, P. Chanson, M. Yaneva, M. Reincke, M. Krsek, M.Toth, S.M. Webb, A. Santos, I. Paiva, I. Komerdus, M. Droste, A. Tabarin, C.J. Strasburger, H. Franz, P.J. Trainer, J. Newell-Price, J.A. Wass, E. Papakokkinou, O. Ragnarsson, ERCUSYN Study Group, Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN. Clin. Endocrinol. (Oxf.). 88, 787–798 (2018)
31.
go back to reference M.A. Wagenmakers, R.T. Netea-Maier, J.B. Prins, T. Dekkers, M. den Heijer, A.R. Hermus, Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? Eur. J. Endocrinol. 167, 687–695 (2012)CrossRefPubMed M.A. Wagenmakers, R.T. Netea-Maier, J.B. Prins, T. Dekkers, M. den Heijer, A.R. Hermus, Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? Eur. J. Endocrinol. 167, 687–695 (2012)CrossRefPubMed
Metadata
Title
Factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission
Authors
Marie Helene Schernthaner-Reiter
Christina Siess
Alois Gessl
Christian Scheuba
Stefan Wolfsberger
Philipp Riss
Engelbert Knosp
Anton Luger
Greisa Vila
Publication date
01-04-2019
Publisher
Springer US
Published in
Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1819-6

Other articles of this Issue 1/2019

Endocrine 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.